Manufacturing Disruption Hits Baxter Cancer Drug Supply In Europe

Baxter International Inc. (NYSE:BAX) has alerted health care professionals to a looming shortage of ifosfamide-based cancer therapies across the European Union, following a technical disruption at a contract manufacturing site. • Baxter International stock is showing downward bias. Where is BAX stock headed? The company said the supply constraint, which affects products marketed as Holoxan, Tronoxal and Mitoxana, is expected to persist until the first quarter of 2027, prompting allocation controls and treatment prioritization measures. Manufacturing Disruption Triggers EU-Wide Supply Crunch The shortage stems from a technical issue at a third-party manufacturing facility that disrupted production planning, inventory systems and product release cycles. The site was also undergoing corrective actions after a regulatory inspection, compounding the disruption. Baxter, the primary supplier of ifosfamide in the EU, said manufacturing has resumed, but output remains limited. As a result, the company is implementing a quota-based distribution system to manage existing inventory until supply normalizes. No Quality Concerns, But Supplies Remain Constrained The company emphasized that the shortage is not linked to any safety, efficacy or quality concerns with the currently available ifosfamide stock. However, supply interruptions are expected to vary by country, with all EU markets likely to experience constraints over time. Ifosfamide is a cytotoxic chemotherapy agent widely used in both adults and children, either alone or in combination with other therapies, to treat a range of malignant conditions. Doctors Urged To Prioritize Existing Patients To mitigate the impact, Baxter is working with the European Medicines Agency and national regulators on coordinated response measures. Health care providers are being advised to secure an adequate supply before initiating new treatment courses. Physicians may need to prioritize patients already undergoing therapy or those with limited alternative treatment options. In some cases, switching to alternative regimens in line with European guidelines or local protocols may be necessary. Baxter stock fell after the company guided fiscal 2026 adjusted earnings between $1.85-$2.05 per share, compared to the consensus of $2.25. Adjusted operating margin is expected to be between 13%-14% The hospital product maker forecasts 2026 sales of $11.24 billion-$11.36 billion, compared to the consensus of $11.31 billion. Baxter expects 2026 sales growth to be flat to increase by 1%. BAX Stock Price Activity: Baxter shares were up slightly at $16.63 at the time of publication on Tuesday according to Benzinga Pro data. Image via Shutterstock